What Happened

Jardine Matheson has signed a deal to acquire I-MED for $3.4 billion in enterprise value, according to the Australian Financial Review's Street Talk column, which broke the story on May 24, 2026.

The deal gives Jardine 100 percent ownership of the largest radiology business in the Asia Pacific region. It was signed over the weekend and announced in London on Monday at approximately 8pm Sydney time, per AFR sources speaking on condition of anonymity.

Bloomberg also reported the deal, though its initial reporting pegged the figure at $2.4 billion — a full billion dollars less than AFR's $3.4 billion enterprise value figure. That's a significant discrepancy that requires clarification.

Who's Involved

I-MED was owned by Permira, a London-based private equity firm. Permira had been exploring an IPO for I-MED — reportedly one of the biggest floats anticipated on the Australian market in 2026. That IPO is now dead.

Jardine Matheson is a 194-year-old conglomerate listed in both London and Singapore. According to AFR's earlier reporting from May 5, 2026, Jardine had been in deep due diligence on this deal with advisers Rothschild and Allens since at least late April.

Private equity selling to a strategic buyer instead of going public is a classic move when the IPO market gets wobbly or when a buyer shows up with a number that beats what public markets would realistically deliver.

Why Jardine Is Doing This

Jardine is in the middle of a deliberate portfolio transformation. According to Simply Wall St, Jardine recently completed a takeover of luxury hotel group Mandarin Oriental, launched a $250 million share buyback, and installed a private equity veteran as its new CEO. The stated goal is capital recycling — moving money out of low-return assets and into high-return ones.

I-MED fits that thesis. Healthcare infrastructure — especially imaging and diagnostics — is a high-margin, defensible business with demographic tailwinds across Asia Pacific. As populations age across Australia and the broader region, demand for radiology services isn't going away.

Simply Wall St projects Jardine's revenue hitting $37.4 billion with $2.7 billion in earnings by 2028. That would require roughly 1.7 percent annual revenue growth. A cash-generating asset like I-MED helps close that gap.

The Problem Jardine Still Has

Jardine still has a serious drag on its books that deal coverage has largely overlooked.

Hongkong Land, Jardine's Greater China property arm, is sitting in a prolonged slump tied to China's ongoing real estate crisis. Simply Wall St flags this explicitly — the $250 million buyback and portfolio moves are positive signals, but they don't solve the structural problem of softness in Greater China property.

So Jardine is essentially buying a healthy Australian healthcare asset while one of its core businesses bleeds in a Chinese real estate market that shows no sign of a clean recovery. The I-MED deal is smart. The Hongkong Land exposure remains a significant liability.

What the Media Is Getting Wrong

Most coverage treats this as a straightforward M&A story.

First, the $1 billion gap between Bloomberg's $2.4 billion figure and AFR's $3.4 billion enterprise value figure needs explanation. Enterprise value vs. equity value can account for some of that, but neither outlet has clarified the discrepancy.

Second, almost no coverage asks what a 194-year-old Anglo-Asian conglomerate buying Australia's biggest radiology chain means for Australian patients and healthcare competition. I-MED operates hundreds of imaging clinics across Australia. Ownership now passes to a foreign conglomerate in the middle of a strategic overhaul. Australian regulators will need to sign off on this, and whether they scrutinize it appropriately is a public interest question.

Third, the IPO collapse deserves scrutiny. When a private equity firm pulls a marquee IPO and sells to a strategic buyer instead, it often signals one of two things: either the IPO market couldn't deliver the price Permira wanted, or the strategic buyer paid a premium that public markets wouldn't have. Either answer reveals something important about valuation realities right now.

What This Means for Regular People

If you're an Australian getting an MRI or a CT scan, there's a real chance that service runs through I-MED. Your radiology provider just changed hands for $3.4 billion.

Jardine's new PE-veteran CEO is focused on capital returns. That's fine for shareholders. But healthcare businesses run by return-focused conglomerates have a track record of cutting costs where patients notice — staffing, wait times, equipment upgrades.

The service quality and pricing of I-MED over the next three to five years will be the real story here. The deal is done. Now comes the part that actually affects people.